Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 3 3 AND SODIUM CHLORIDE 0 3 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 3 3 AND SODIUM CHLORIDE 0 3 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride replaces potassium ions, essential for maintaining intracellular fluid balance, nerve impulse transmission, and muscle contraction. Dextrose provides a source of calories and may help prevent ketosis. Sodium chloride replaces sodium and chloride ions, maintaining osmotic pressure and acid-base balance.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion; rate not to exceed 0.5-1 mEq/kg/hour (maximum 10-20 mEq/hour) with continuous ECG monitoring; typical adult dose: 20-40 mEq potassium chloride in 1 L of the specified solution infused over 4-6 hours.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Potassium has a biological half-life of approximately 8 hours in healthy adults, but this is highly variable based on renal function and total body stores. The terminal elimination half-life is not classically defined as it follows multicompartment kinetics; the redistribution half-life is about 1 hour. Clinical context: half-life is prolonged in renal impairment and with high potassium intake.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Potassium is primarily excreted by the kidneys (90%), with small amounts lost in feces (10%). Minor losses occur through sweat. Renal excretion involves glomerular filtration and tubular secretion, with aldosterone-regulated reabsorption. Biliary excretion is negligible.
Category C
Category A/B
Electrolyte
Electrolyte